Jennison Associates LLC Bluebird Bio, Inc. Transaction History

Jennison Associates LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$5.77 - $8.49 $87,496 - $128,742	-15,164 Reduced 12.46%	106,557 $737,000
Q3 2022 Nov 01, 2022	BUY	$3.75 - $7.39 $456,453 - $899,518	121,721 New	121,721 $770,000
Q4 2019 Feb 07, 2020	SELL	$46.96 - $61.67 $8.54 Million - $11.2 Million	-181,913 Closed	0 $0
Q2 2019 Aug 06, 2019	SELL	$75.84 - $105.21 $7.66 Million - $10.6 Million	-100,938 Reduced 35.69%	181,913 $0
Q1 2019 May 10, 2019	SELL	$64.44 - $104.11 $34,346 - $55,490	-533 Reduced 0.19%	282,851 $44.5 Million
Q4 2018 Feb 06, 2019	SELL	$59.1 - $93.26 $13.8 Million - $21.8 Million	-233,600 Reduced 45.19%	283,384 $28.1 Million
Q3 2018 Nov 08, 2018	BUY	$88.86 - $117.49 $377,121 - $498,627	4,244 Added 0.83%	516,984 $75.5 Million
Q2 2018 Aug 02, 2018	BUY	$99.64 - $127.59 $964,216 - $1.23 Million	9,677 Added 1.92%	512,740 $80.5 Million
Q1 2018 Apr 20, 2018	SELL	$105.8 - $150.94 $3.98 Million - $5.68 Million	-37,634 Reduced 6.96%	503,063 $85.9 Million
Q4 2017 Jan 25, 2018	SELL	$81.25 - $130.7 $10.1 Million - $16.2 Million	-124,159 Reduced 18.67%	540,697 $96.3 Million
Q3 2017 Nov 03, 2017	BUY	$57.74 - $91.42 $38.4 Million - $60.8 Million	664,856	664,856 $91.3 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.